At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CR crane
Post-Mkt 07-21 19:49:35 EDT
217.38
-0.16
-0.07%
盘后217.38
+0.000.00%
17:08 EDT
High222.27Low216.24Vol508.94K
Open219.24D1 Closing217.54Amplitude2.77%
Mkt Cap12.52BTradable Cap10.60BTotal Shares57.60M
T/O110.99MT/O Rate1.04%Tradable Shares48.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Dow Jones  ·  07-20 19:30
Press Release: Standard Biotools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Crane (CR) Acquires PSI, Is The Stock Near Fair Value?
Simply Wall St.  ·  07-20 18:21
Crane (CR) Acquires PSI, Is The Stock Near Fair Value?
Analysts Offer Insights on Industrial Goods Companies: ABB Ltd (OtherABBNY) and Crane Company (CR)
TIPRANKS  ·  07-20 15:00
Analysts Offer Insights on Industrial Goods Companies: ABB Ltd (OtherABBNY) and Crane Company (CR)
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
GlobeNewswire  ·  07-14
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
GlobeNewswire  ·  07-07
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Crane (CR) Leaves Russell Defensive Indexes, Is The Premium Already Priced In?
Simply Wall St.  ·  07-06
Crane (CR) Leaves Russell Defensive Indexes, Is The Premium Already Priced In?
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
GlobeNewswire  ·  06-30
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Crane Updates Financial Calendar with Second-quarter 2026 Earnings Release, Teleconference Schedule
Reuters  ·  06-29
Crane Updates Financial Calendar with Second-quarter 2026 Earnings Release, Teleconference Schedule
Crane Company Announces Date for Second Quarter 2026 Earnings Release and Teleconference
THOMSON REUTERS  ·  06-29
Crane Company Announces Date for Second Quarter 2026 Earnings Release and Teleconference
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
GlobeNewswire  ·  06-14
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
GlobeNewswire  ·  06-14
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Honda Recalls Over One Million Vehicles in the U.S., Primarily Affecting CR-V and Accord Hybrid Models
Deep News  ·  06-11
Honda Recalls Over One Million Vehicles in the U.S., Primarily Affecting CR-V and Accord Hybrid Models
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
GlobeNewswire  ·  06-11
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
GlobeNewswire  ·  06-11
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
GlobeNewswire  ·  06-11
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
GlobeNewswire  ·  06-11
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
Crane NXT unit Antares Vision debuts laser spectroscopy leak detection tech at ProPak Asia
Reuters  ·  06-09
Crane NXT unit Antares Vision debuts laser spectroscopy leak detection tech at ProPak Asia
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
GlobeNewswire  ·  06-03
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
Crane Is Maintained at Buy by DA Davidson
Dow Jones  ·  06-02
Crane Is Maintained at Buy by DA Davidson
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
GlobeNewswire  ·  06-01
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Introduction

Company Name.
crane
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.
Issue price:
--